Progress in Diagnosis and Treatment of Vulvar Squamous Cell Carcinoma

doi:10.12280/gjfckx.20210298

Abstract

Abstract:

The incidence of vulvar squamous cell carcinoma (VSCC) increases every year. Although the diagnosis and treatment of tumors are improving, the recurrence rate and death rate of late VSCC have not decreased obviously. Due to the rarity of VSCC, there are no randomized clinical trials to compare the advantages and disadvantages of different treatments. Traditional treatments mainly include surgery and radiotherapy, and the changing trend of the surgical methods tends to be more conservative surgical scope to achieve greater therapeutic effect for diseases. The application of laparoscopic inguinal lymph node dissection and sentinel lymph node biopsy is also gradually widespread, and immunotherapy is also on the rise. The purpose of this paper is to review the latest research progress in the diagnosis, surgical treatment, radiotherapy and chemotherapy of VSCC, to provide reference for follow-up clinical diagnosis and treatment.

Key words: Vulvar neoplasms, Carcinoma,squamous cell, Papillomaviridae, Gynecologic surgical procedures, Chemoradiotherapy,adjuvant, Sentinel lymph node, Sentinel lymph node biopsy, Prognosis

QIN Zhao-juan, ZHENG Ai. Progress in Diagnosis and Treatment of Vulvar Squamous Cell Carcinoma[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 34-38.

References 28

[1]	Xing D, Fadare O. Molecular events in the pathogenesis of vulvar squamous cell carcinoma[J]. Semin Diagn Pathol, 2021, 38(1):50-61. doi: 10.1053/j.semdp.2020.09.010. doi: 10.1053/j.semdp.2020.09.010
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[3]	Rogers LJ, Cuello MA. Cancer of the vulva[J]. Int J Gynaecol Obstet, 2018, 143(Suppl 2):4-13. doi: 10.1002/ijgo.12609. doi: 10.1002/ijgo.12609
[4]	倪雪, 张三元. 外阴鳞癌治疗进展[J]. 国际妇产科学杂志, 2017, 44(6):686-689. doi: 10.3969/j.issn.1674-1870.2017.06.020. doi: 10.3969/j.issn.1674-1870.2017.06.020
[5]	Allo G, Yap ML, Cuartero J, et al. HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors[J]. Int J Gynecol Pathol, 2020, 39(4):391-399. doi: 10.1097/PGP.0000000000000620. doi: 10.1097/PGP.0000000000000620
[6]	Eva LJ, Sadler L, Fong KL, et al. Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma[J]. Gynecol Oncol, 2020, 157(2):450-455. doi: 10.1016/j.ygyno.2020.01.029. doi: 10.1016/j.ygyno.2020.01.029
[7]	Singh N, Gilks CB. Vulval squamous cell carcinoma and its precursors[J]. Histopathology, 2020, 76(1):128-138. doi: 10.1111/his.13989. doi: 10.1111/his.13989
[8]	谢玲玲, 林荣春, 林仲秋. 《2020NCCN外阴鳞癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(3):239-244. doi: 10.19538/j.fk2020030114. doi: 10.19538/j.fk2020030114
[9]	Xiao X, Meng YB, Bai P, et al. Vulvar Cancer in China: Epidemiological Features and Risk Analysis[J]. J Cancer, 2017, 8(15):2950-2958. doi: 10.7150/jca.20496. doi: 10.7150/jca.20496 pmid: 28928886
[10]	Muigai J, Jacob L, Dinas K, et al. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices[J]. Oncotarget, 2018, 9(9):8725-8730. doi: 10.18632/oncotarget.23848. doi: 10.18632/oncotarget.23848
[11]	Prieske K, Woelber L, Muallem MZ, et al. Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study[J]. Gynecol Oncol, 2021, 161(2):442-448. doi: 10.1016/j.ygyno.2021.02.025. doi: 10.1016/j.ygyno.2021.02.025
[12]	Milliken S, May J, Sanderson PA, et al. Reducing the radicality of surgery for vulvar cancer: are smaller margins safer?[J]. Minerva Obstet Gynecol, 2021, 73(2):160-165. doi: 10.23736/S0026-4784.20.04743-7. doi: 10.23736/S0026-4784.20.04743-7
[13]	Pouwer AW, Arts HJ, van der Velden J, et al. Limiting the morbidity of inguinofemoral lymphadenectomy in vulvar cancer patients; a review[J]. Expert Rev Anticancer Ther, 2017, 17(7):615-624. doi: 10.1080/14737140.2017.1337513. doi: 10.1080/14737140.2017.1337513
[14]	Xu J, Duan K, Guan X, et al. Laparoendoscopic single-site inguinal lymphadenectomy in gynecology: preliminary experience at a single institution[J]. Arch Gynecol Obstet, 2020, 302(2):497-503. doi: 10.1007/s00404-020-05649-5. doi: 10.1007/s00404-020-05649-5
[15]	Coleman RL, Ali S, Levenback CF, et al. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173[J]. Gynecol Oncol, 2013, 128(2):155-159. doi: 10.1016/j.ygyno.2012.11.034. doi: 10.1016/j.ygyno.2012.11.034 pmid: 23201592
[16]	Hermann CE, Nasioudis D, Mastroyannis SA, et al. Utilization and outcomes of sentinel lymph node biopsy in patients with early stage vulvar cancer[J]. Int J Gynecol Cancer, 2021, 31(1):40-44. doi: 10.1136/ijgc-2020-001934. doi: 10.1136/ijgc-2020-001934
[17]	Winarno AS, Mondal A, Martignoni FC, et al. The potential risk of contralateral non-sentinel groin node metastasis in women with early primary vulvar cancer following unilateral sentinel node metastasis: a single center evaluation in University Hospital of Düsseldorf[J]. BMC Womens Health, 2021, 21(1):23. doi: 10.1186/s12905-020-01165-5. doi: 10.1186/s12905-020-01165-5
[18]	Mazumder K, Elangovan A, Rai B, et al. Conventional radiotherapy and intensity-modulated radiotherapy in carcinoma vulva: An experience from a tertiary medical center of India[J]. South Asian J Cancer, 2019, 8(1):41-43. doi: 10.4103/sajc.sajc_66_17. doi: 10.4103/sajc.sajc_66_17 pmid: 30766852
[19]	Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study[J]. J Natl Cancer Inst, 2015, 107(3):dju426. doi: 10.1093/jnci/dju426. doi: 10.1093/jnci/dju426
[20]	Borella F, Preti M, Bertero L, et al. Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review[J]. Int J Mol Sci, 2020, 22(1):190. doi: 10.3390/ijms22010190. doi: 10.3390/ijms22010190
[21]	Mantovani G, Fragomeni SM, Inzani F, et al. Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies[J]. J Cancer Res Clin Oncol, 2020, 146(7):1647-1658. doi: 10.1007/s00432-020-03226-6. doi: 10.1007/s00432-020-03226-6 pmid: 32335720
[22]	Olawaiye A, Lee LM, Krasner C, et al. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva[J]. Gynecol Oncol, 2007, 106(3):628-630. doi: 10.1016/j.ygyno.2007.05.006. doi: 10.1016/j.ygyno.2007.05.006
[23]	徐婷, 陈泽洋, 吴玉梅. 外阴鳞状细胞癌术后复发的影响因素[J]. 现代肿瘤医学, 2020, 28(7):1194-1198. doi: 10.3969/j.issn.1672-4992.2020.07.032. doi: 10.3969/j.issn.1672-4992.2020.07.032
[24]	丁岩, 张梦蕾, 丁景新, 等. 外阴癌腹股沟淋巴结清扫术的研究新进展[J]. 中国计划生育和妇产科, 2019, 11(10):24-29. doi: 10.3969/j.issn.1674-4020.2019.10.07. doi: 10.3969/j.issn.1674-4020.2019.10.07
[25]	叶桂萍, 周颖, 孙金, 等. 外阴癌患者发生腹股沟淋巴结转移的影响因素分析[J]. 癌症进展, 2019, 17(12):1469-1472. doi: 10.11877/j.issn.1672-1535.2019.17.12.28. doi: 10.11877/j.issn.1672-1535.2019.17.12.28
[26]	Winarno AS, Mondal A, Martignoni FC, et al. The potential risk of contralateral non-sentinel groin node metastasis in women with early primary vulvar cancer following unilateral sentinel node metastasis: a single center evaluation in University Hospital of Düsseldorf[J]. BMC Womens Health, 2021, 21(1):23. doi: 10.1186/s12905-020-01165-5. doi: 10.1186/s12905-020-01165-5
[27]	El Afandy A, Soliman H, El Sherbiny M, et al. Groin recurrence in patients with early vulvar cancer following superficial inguinal node dissection[J]. J Egypt Nat Canc Inst, 2013, 25(3):121-124. doi: 10.1016/j.jnci.2013.05.001. doi: 10.1016/j.jnci.2013.05.001
[28]	Milliken S, May J, Sanderson PA, et al. Reducing the radicality of surgery for vulvar cancer: are smaller margins safe?[J]. Minerva ginecologica, 2021, 73(2):160-165. doi: 10.23736/S0026-4784.20.04743-7. doi: 10.23736/S0026-4784.20.04743-7